<DOC>
	<DOCNO>NCT02667639</DOCNO>
	<brief_summary>The purpose fist human study evaluate safety tolerability RPH-104 human .</brief_summary>
	<brief_title>First Human Study RPH-104</brief_title>
	<detailed_description />
	<criteria>Healthy subject . Male female subject 18 35 year old ( inclusive ) . Subject normal body weight determine body mass index ( BMI ) 18 kg/m² 28 kg/m² ( inclusive ) within body weight ≥50kg ≤120kg . Subjects history presence cardiovascular , respiratory , hepatic , renal , gastrointestinal , endocrinological , dermatological , neurological , psychiatric , hematological immunological disorder Positive immunoglobulinM ( IgM ) antibodies Epstein Barr virusviral capsid antigen ( IgMantiEBVVCA ) Cytomegalovirus ( CMV ) . Positive Quantiferon TBGold ( TB ) test . Positive Human Immunodeficiency Virus1/2 antibody ( HIV1/2Ab ) . Positive Hepatitis B surface antigen ( HBsAg ) , Hepatitis C virus antibody ( HCVAb ) .</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>35 Years</maximum_age>
	<verification_date>January 2016</verification_date>
	<keyword>safety</keyword>
	<keyword>tolerability</keyword>
	<keyword>RPH-104</keyword>
	<keyword>RPH104</keyword>
</DOC>